PPA1 and lung disorder: In this regard, the development of small molecule inhibitors, which can compete with specific docking motifs of PP1/PP2A regulatory subunits thus disrupting selective PPase interactomes, may open a new avenue in the treatment of cardiovascular and pulmonary diseases.